Please use this identifier to cite or link to this item:
https://olympias.lib.uoi.gr/jspui/handle/123456789/17273Full metadata record
| DC Field | Value | Language |
|---|---|---|
| dc.contributor.author | Katsanos, K. H. | en |
| dc.contributor.author | Briasoulis, E. | en |
| dc.contributor.author | Tsekeris, P. | en |
| dc.contributor.author | Batistatou, A. | en |
| dc.contributor.author | Bai, M. | en |
| dc.contributor.author | Tolis, C. | en |
| dc.contributor.author | Capizzello, A. | en |
| dc.contributor.author | Panelos, I. | en |
| dc.contributor.author | Karavasilis, V. | en |
| dc.contributor.author | Christodoulou, D. | en |
| dc.contributor.author | Tsianos, E. V. | en |
| dc.date.accessioned | 2015-11-24T18:38:04Z | - |
| dc.date.available | 2015-11-24T18:38:04Z | - |
| dc.identifier.issn | 1756-9966 | - |
| dc.identifier.uri | https://olympias.lib.uoi.gr/jspui/handle/123456789/17273 | - |
| dc.rights | Default Licence | - |
| dc.subject | radioprotective agent | en |
| dc.subject | radiation proctitis | en |
| dc.subject | topical application | en |
| dc.subject | small-intestine | en |
| dc.subject | rectal-cancer | en |
| dc.subject | rat colon | en |
| dc.subject | wr-2721 | en |
| dc.subject | toxicity | en |
| dc.subject | injury | en |
| dc.subject | protection | en |
| dc.title | Randomized phase II exploratory study of prophylactic amifostine in cancer patients who receive radical radiotherapy to the pelvis | en |
| heal.type | journalArticle | - |
| heal.type.en | Journal article | en |
| heal.type.el | Άρθρο Περιοδικού | el |
| heal.identifier.primary | Doi 10.1186/1756-9966-29-68 | - |
| heal.identifier.secondary | <Go to ISI>://000280093900001 | - |
| heal.identifier.secondary | http://www.jeccr.com/content/pdf/1756-9966-29-68.pdf | - |
| heal.language | en | - |
| heal.access | campus | - |
| heal.recordProvider | Πανεπιστήμιο Ιωαννίνων. Σχολή Επιστημών και Τεχνολογιών. Τμήμα Βιολογικών Εφαρμογών και Τεχνολογιών | el |
| heal.publicationDate | 2010 | - |
| heal.abstract | Background: This study aimed to investigate the efficacy of prophylactic amifostine in reducing the risk of severe radiation colitis in cancer patients receiving radical radiotherapy to the pelvis. Methods: Patients with pelvic tumours referred for radical radiotherapy who consented participation in this trial, were randomly assigned to receive daily amifostine (A) (subcutaneously, 500 mg flat dose) before radiotherapy or radiotherapy alone (R). Sigmoidoscopy and blinded biopsies were scheduled to conduct prior to initiation and following completion of radiotherapy and again 6 to 9 months later. Radiation colitis was assessed by clinical, endoscopic and histolopathological criteria. Results: A total 44 patients were enrolled in this trial, the majority with rectal (20 patients) and cervical cancer (12 patients) and were assigned 23 in R arm and 21 in the A arm. In total 119 sigmoidoscopies were performed and 18 patients (18/44, 40.9%) were diagnosed with radiation colitis (15 grade 1 and 2, and 3 grade 3 and 4). Of them, 6 patients belonged to the A group (6/21, 28.6%) and 12 to the R group (12/23, 52.2%). Acute and grade IV radiation colitis was only developed in four patients (17.4%) in the R group. Amifostine side effects were mild. Amifostine treated patients were less likely to develop histologically detectable mucosal lesions, which indicate protection from acute mucosal injury. Conclusions: Amifostine given subcutaneously can lower the risk of acute severe radiation colitis in patients who receive radical radiotherapy to pelvic tumors. | en |
| heal.journalName | Journal of Experimental & Clinical Cancer Research | en |
| heal.journalType | peer reviewed | - |
| heal.fullTextAvailability | TRUE | - |
| Appears in Collections: | Άρθρα σε επιστημονικά περιοδικά ( Ανοικτά) | |
Files in This Item:
| File | Description | Size | Format | |
|---|---|---|---|---|
| Katsanos-2010-Randomized phase II.pdf | 816.79 kB | Adobe PDF | View/Open Request a copy |
This item is licensed under a Creative Commons License
